Effect of mergers and acquisitions on drug discovery : perspective from a case study of a Japanese pharmaceutical company
(2008) In Drug Discovery Today 13(1-2). p.86-93- Abstract
The pharmaceutical industry has experienced intermittent waves of mergers and acquisitions (M&As) since the 1980s and recently appeared to be in yet another wave. Previous studies indicated rather negative impacts of consolidation on research and development, suggesting that they do not necessarily lead to long-term reinforcement of research capabilities, although they may enrich the drug pipeline in the short term. However, recent studies have implied a positive side in terms of knowledge-base transfer. Further micro-organizational studies suggested that scientists learned new knowledge and approaches from partner scientists and improved their performance and innovation. These findings imply that measures for the scientist-level... (More)
The pharmaceutical industry has experienced intermittent waves of mergers and acquisitions (M&As) since the 1980s and recently appeared to be in yet another wave. Previous studies indicated rather negative impacts of consolidation on research and development, suggesting that they do not necessarily lead to long-term reinforcement of research capabilities, although they may enrich the drug pipeline in the short term. However, recent studies have implied a positive side in terms of knowledge-base transfer. Further micro-organizational studies suggested that scientists learned new knowledge and approaches from partner scientists and improved their performance and innovation. These findings imply that measures for the scientist-level integration after M&As would reinforce fundamental research capabilities in the long term.
(Less)
- author
- Shibayama, Sotaro LU ; Tanikawa, Kunihiro ; Fujimoto, Ryuhei and Kimura, Hiromichi
- publishing date
- 2008-01
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Drug Discovery Today
- volume
- 13
- issue
- 1-2
- pages
- 8 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:18190869
- scopus:37649033180
- ISSN
- 1359-6446
- DOI
- 10.1016/j.drudis.2007.10.015
- language
- English
- LU publication?
- no
- id
- be989541-8502-40b4-acda-5397cf13c10c
- date added to LUP
- 2017-04-13 17:47:50
- date last changed
- 2024-03-31 07:45:15
@article{be989541-8502-40b4-acda-5397cf13c10c,
abstract = {{<p>The pharmaceutical industry has experienced intermittent waves of mergers and acquisitions (M&As) since the 1980s and recently appeared to be in yet another wave. Previous studies indicated rather negative impacts of consolidation on research and development, suggesting that they do not necessarily lead to long-term reinforcement of research capabilities, although they may enrich the drug pipeline in the short term. However, recent studies have implied a positive side in terms of knowledge-base transfer. Further micro-organizational studies suggested that scientists learned new knowledge and approaches from partner scientists and improved their performance and innovation. These findings imply that measures for the scientist-level integration after M&As would reinforce fundamental research capabilities in the long term.</p>}},
author = {{Shibayama, Sotaro and Tanikawa, Kunihiro and Fujimoto, Ryuhei and Kimura, Hiromichi}},
issn = {{1359-6446}},
language = {{eng}},
number = {{1-2}},
pages = {{86--93}},
publisher = {{Elsevier}},
series = {{Drug Discovery Today}},
title = {{Effect of mergers and acquisitions on drug discovery : perspective from a case study of a Japanese pharmaceutical company}},
url = {{http://dx.doi.org/10.1016/j.drudis.2007.10.015}},
doi = {{10.1016/j.drudis.2007.10.015}},
volume = {{13}},
year = {{2008}},
}